Cogenics

Acquired By Beckman Coulter
Gene synthesis, sequencing, and molecular biology services are provided.

About Cogenics

Cogenics is a Healthcare company, and was acquired by Beckman Coulter in April 2009. Gene synthesis, sequencing, and molecular biology services are provided.

Company details

Gene synthesis, sequencing, and molecular biology services are offered by Cogenics in the biotechnology sector. Next-generation sequencing, Sanger sequencing, PCR, and related techniques are encompassed within these offerings. Plasmid preparation, oligo synthesis, and nucleic acid extraction are included among the core services. Preclinical and clinical support is provided through GLP-compliant testing and CLIA-certified variant confirmation. Research in gene therapy, cancer, and infectious diseases is facilitated by these capabilities.

Key Metrics

Investors in Cogenics

Cogenics has secured backing from 1 investor. Prominent investors backing the company include Beckman Coulter.

All
InvestorDescriptionFounded YearDomainLocation
Clinical diagnostic products are manufactured for biomedical testing.
1935beckmancoulter.comBrea, United States
Premium access

Investor details for Cogenics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Web traffic of Cogenics

Websites that share an audience with Cogenics (cogenics.com).

Similar websites

Websites whose visitors overlap most with Cogenics. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
beckmangenomics.com
93%
View details
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Cogenics

Gene synthesis, sequencing, and molecular biology services are offered by Cogenics in the biotechnology sector. Next-generation sequencing, Sanger sequencing, PCR, and related techniques are encompassed within these offerings. Plasmid preparation, oligo synthesis, and nucleic acid extraction are included among the core services. Preclinical and clinical support is provided through GLP-compliant testing and CLIA-certified variant confirmation. Research in gene therapy, cancer, and infectious diseases is facilitated by these capabilities.

Cogenics has 1 investor. Key investors include Beckman Coulter.

Yes. Cogenics was acquired by Beckman Coulter in April 2009.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available